Creatine monohydrate supplementation does not increase muscle strength, lean body mass, or muscle phosphocreatine in patients with myotonic dystrophy type 1.
about
Creatine for treating muscle disordersCreatine for treating muscle disordersPharmacological treatment for muscle weakness and wasting in myotonic dystrophyDrug treatment for myotoniaCreatine for treating muscle disordersCreatine fails to augment the benefits from resistance training in patients with HIV infection: a randomized, double-blind, placebo-controlled study.Diagnostics and therapy of muscle channelopathies--Guidelines of the Ulm Muscle Centre.Can the use of creatine supplementation attenuate muscle loss in cachexia and wasting?Creatine, L-carnitine, and ω3 polyunsaturated fatty acid supplementation from healthy to diseased skeletal muscle.Myotonic dystrophy: therapeutic strategies for the future.Creatine as a therapeutic strategy for myopathies.Lower limb muscle impairment in myotonic dystrophy type 1: the need for better guidelines.Treatment of muscle weakness in neuromuscular disorders.Can Creatine Supplementation Improve Body Composition and Objective Physical Function in Rheumatoid Arthritis Patients? A Randomized Controlled Trial.Creatine has no beneficial effect on skeletal muscle energy metabolism in patients with single mitochondrial DNA deletions: a placebo-controlled, double-blind 31P-MRS crossover study.Efficacy and safety of creatine supplementation in childhood-onset systemic lupus erythematosus: a randomized, double-blind, placebo-controlled, crossover trial.
P2860
Q24202243-28421A06-2CD4-4195-9B37-C376B74D5E43Q24236598-474508D8-7840-4799-9847-09F1D39B261AQ24240183-3FBEE3E7-767F-4418-BF8A-0B6437CAE587Q24244905-F417B3C2-B19A-4C20-B7EE-FB12E922C2A3Q24246414-B816C582-3F80-4AC6-A48C-ED44C90D3EA4Q33412387-3325A7A4-3C33-4D70-945A-78772A0C8823Q33807683-47914A79-7B30-48C2-9158-40F3F42BCF55Q34000393-9B34A51E-1D82-4E8F-A97A-FC27C16789A9Q34177044-12ED8255-6B2F-4D16-A683-DF7615DE28DBQ37329544-1E7975CF-D535-4AC5-A943-39F7C07AE041Q37852586-F4E9F5CE-F89F-402C-9311-0B7E66F280BFQ38268524-12FAC15B-5DED-4656-A047-73537E61CA54Q38845507-82C467FB-5E96-48B0-B154-BA30FAC3DD84Q40491482-6018F24E-D81E-45A3-8E75-BFE776A41371Q46416690-6FAD9039-7255-4545-91DB-74FB9123CFC4Q48067858-A446DEE7-36B3-4E5D-9C97-A9D4E15A0620
P2860
Creatine monohydrate supplementation does not increase muscle strength, lean body mass, or muscle phosphocreatine in patients with myotonic dystrophy type 1.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Creatine monohydrate supplemen ...... ith myotonic dystrophy type 1.
@en
Creatine monohydrate supplemen ...... ith myotonic dystrophy type 1.
@nl
type
label
Creatine monohydrate supplemen ...... ith myotonic dystrophy type 1.
@en
Creatine monohydrate supplemen ...... ith myotonic dystrophy type 1.
@nl
prefLabel
Creatine monohydrate supplemen ...... ith myotonic dystrophy type 1.
@en
Creatine monohydrate supplemen ...... ith myotonic dystrophy type 1.
@nl
P2093
P2860
P356
P1433
P1476
Creatine monohydrate supplemen ...... ith myotonic dystrophy type 1.
@en
P2093
Douglas Mahoney
Heather Naylor
Mark Tarnopolsky
Terry Thompson
Timothy J Doherty
P2860
P356
10.1002/MUS.10527
P577
2004-01-01T00:00:00Z